Matt Lucas

Matt Lucas

Company: Black Diamond

Job title: SVP, Drug Discovery


Utilizing a CNS Penetrant MasterKey Inhibitor to Access the Blood Brain Barrier to Treat Glioblastoma & Brain Metastasis in NSCLC 10:00 am

Revealing BDTX-1535, a CNS penetrant MasterKey inhibitor of EGFR mutations which demonstrates in vivo efficacy and has the potential to treat patients with NSCLC and GBM Targeting unmet medical needs in EGFR-mutated NSCLC EGFR-mutated GBM Presenting preclinical data that support opportunity for progression to clinical studies and therapeutic effect in both indicationsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.